Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Open evidence library

Search the archive.

Current and older evidence is free during beta. Sign in for unlimited card access and full source downloads.

Matching cards
2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Innovation Turns Disease

Vaccines innovation are key to preventing extinction level pandemics

LeMay, Michael C., and Angela Quinn 2016. Global pandemic threats: a reference handbook. Santa Barbara, CA, ABC-CLIO, 2016, books.google.com/books?hl=en&lr=&id=_UzODAAAQBAJ&oi=fnd&pg=PP1&dq=%22pandemic%22 AND %22extinction%22&ots=1ao_EIX8Ph&sig=iJgSKIO4IOavSBCG78LgXf7dS6c#v=onepage&q=%22extinction%22&f=false. Accessed 28 June 2017. //PHOPS

Vaccines Are the Key to Preventing Global Disease Pandemics Angela Quinn If you've ever seen an episode of the Walking Dead, you know all too well what the threat of a global, pandemic outbreak of a disease could mean for mankind. As world travel becomes more possible with the expansion of the airline industry and countries around the world continue to import one another's goods, diseases which were once endemic to one region of the world can quickly become a pandemic nightmare for the entire world. Vaccines are the key to eliminating communicable diseases and preventing such global pandemics. Every 20 seconds, a child in the world dies from a vaccine-preventable disease (United Nations Foundation, 201 5a). Vaccines have been referred to as one of the most important innovations of mankind. Vaccines have been responsible for eliminating one of the world's most harmful and deadly diseases, smallpox. Thanks to global vaccine programs, the World Health Organization declared the last case of smallpox in 1977 (CDC, 2002). Controlling a global pandemic through vaccination programs depends on a number of factors, including cost, access to vaccines, awareness of the risks of disease, and most importantly, the acceptance that vaccines are safe and effective in preventing global pandemics.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Innovation Turns Disease

Innovation resolves pandemics---prevention, detection, response

WHO ‘22. “COVID-19 Research and Innovation - Powering the world's pandemic response – now and in the future, February 2022 - World.” ReliefWeb, United Nations Office for the Coordination of Humanitarian Affairs, 24 February 2022, https://reliefweb.int/report/world/covid-19-research-and-innovation-powering-world-s-pandemic-response-now-and-future. Accessed 28 June 2023. //QSMIT

At the request of its 194 Member States in May 2015, the World Health Organization (WHO) convened a broad network of experts to develop an R&D Blueprint for Action to Prevent Epidemics. A global strategy and preparedness plan was developed to allow for the rapid activation of research before and during epidemics.

Its aim is to fast-track the availability of effective tests, vaccines, medicines and social science that can be used to save lives and avert large- scale crisis, enhancing traditional epidemiology and public health responses with knowledge and skills from a number of areas.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Innovation Turns Disease

Innovation solves disease

Thomas Peter Stossel 1-4-2017. ( Thomas Peter Stossel. "Removing barriers to medical innovation." American Enterprise Institute. Web. 1-4-2017. accessed 6-26-2017. < https://www.aei.org/publication/912939/ >. Phops)

The second era of medical innovations came in the 19th century with the establishment of universities and independent institutes in Europe, and subsequently in North America. Innovations originating from these institutions included a wide variety of revolutionary treatments: the identification and potential eradication of disease-spreading insects; effective treatments of infectious disease with antitoxins and antibiotics; vaccines to prevent diphtheria, pertussis, tetanus, and polio; anticoagulants (“blood thinners”); and vitamin and hormone-replacement therapies.

In this second innovation era, medical advances did in fact largely arise in universities and research institutes. Private industry’s role was to provide manufacturing capabilities that enabled the discoveries to benefit patients, and it was the principal source of the chemical compounds that clinicians — often in academic settings — tested for therapeutic effects.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Innovation Turns Disease

Innovation is responsible for all medical advancements ever

Thomas Peter Stossel 1-4-2017. ( Thomas Peter Stossel. "Removing barriers to medical innovation." American Enterprise Institute. Web. 1-4-2017. accessed 6-26-2017. < https://www.aei.org/publication/912939/ >. Phops)

Enormous improvements in human health have taken place over the last half-century. Americans live, on average, a decade longer. The most prevalent cause of mortality in the United States — cardiovascular disease, which causes heart attacks and strokes — has decreased by over 50%. Cancer, the number-two cause, has become far more treatable, and cancer mortality rates have plummeted in recent years. A few decades ago, it was common to see individuals whom arthritis had deformed and condemned to immobility and chronic pain. Now, such victims are uncommon. Mental-hospital wards that used to house patients with intractable psychoses and depression either sit empty or have been repurposed. The outbreak of the HIV/AIDS epidemic in the 1980s elicited apocalyptic predictions that it would bankrupt the health-care system. But within two decades, many HIV-infected individuals were living normal, albeit medicated lives. The driving force behind these remarkable improvements is unquestionably medical innovation: new technologies including medications, medical devices, and improved medical procedures. But most people are unaware of who or what deserves our gratitude for these advances.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Innovation Turns Disease

Innovation key to infection control – checks pandemic-level outbreaks

Patterson 15 (Te-Erika, “Innovative Healthcare Technology Is Leading The Fight Against Infectious Disease,” Jan 6, https://www.forbes.com/sites/sungardas/2015/01/06/innovative-healthcare-technology-is-leading-the-fight-against-infectious-disease/#3627d9a2d9a2)

The healthcare industry's battle against infectious disease is being fought with innovative technology. Gone are the days when patients found to be exposed to infectious diseases could wander out into the general public. This is good news for you, unless of course, you’re Craig Spencer, the last known person in the U.S. to be diagnosed with Ebola. He caused a frenzy when he ventured out into New York and officials tried to chart his whereabouts and reach anyone with whom he may have been in contact. Although Spencer has been declared free of Ebola and there are no longer any active infections in the U.S., according to a study published in Consumer Healthday, only 6% of American hospitals have infection control procedures in place to effectively and safely handle Ebola patients. There are many other more commonly found infectious diseases at hospitals such as influenza, and MRSA, which like Ebola, could get out of control if not properly managed. According to a report by the Center For Disease Control, hospital Acquired Infections (HAIs) have caused approximately 99,000 deaths in the U.S. per year. Even with these groundbreaking technologies in place, the CDC still recommends that medical centers take added precautions to reduce public exposure to communicable diseases. By tracking patients, staff, visitors and mobile medical equipment, hospital officials can instantly generate reports identifying all people and equipment that have come into contact with an infected individual. By allowing Gigi to roll in and blast away the contagion, fewer hospital staff members are exposed to life threatening illnesses. By using AmWell virtual hospital consultations, fewer healthy patients are exposed to those with more life threatening and contagious diseases. These tactics, if employed properly, will give both hospital leaders and the general public peace of mind that they can immediately isolate affected individuals and take real-time action to keep the public safe.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Innovation Turns Disease

Innovation, especially in precision medicine, key to preventing disease.

Razzak et. al 03-16-2019 (Muhammad Imran Razzak - 1Advanced Analytics Institute, University of Technology, Sydney, Australia. Muhammad Imran - college of applied computer science, Kind Saud University. Guandong Xu - Corresponding author. "Big data analytics for preventitive medicine." Published by: PubMed Central. Accessed 3-3-2023. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088441/) MSUCB

Exponential time increase in data made tough to get useful information form that data. Traditional methods showed much performance; however, their predictive power is limited as traditional analysis deals only with primary analysis, whereas data analytics deals with secondary analysis. Data mining is the digging or mining of data from many dimensions or perspectives through data analysis tools to find prior unknown pattern and relationship in data that may be used as valid information; moreover, it makes the use of this extracted information to build predictive model. It has been used intensively and extensively by many organizations especially in healthcare sector. Data mining is not a magic wand but in fact a big giant tool that does not discover solutions without guidance. Data mining is useful for the following purposes: Exploratory analysis: Examining the data to summarize its main characteristics. Descriptive modeling: Partitioning of the data into subgroups based on its properties. Predictive modeling: Forecasting information form existing data. Discovering pattern: Discover pattern that occur frequently. Retrieval by content: Discovering hidden patterns Big data and machine learning holds great potential for Healthcare providers to systematically use data and analytics to discover interesting pattern that are previously unknown and uncover the inefficiencies from vast data stores in order to build predictive models for best practices that improve quality of healthcare as well as reduces the cost. EHR system are producing huge amount of data on daily basis which is a rich source of information that can be used by healthcare organization to explore the interesting fact and findings that can help to improve patient care. Figure 1 shows the data analytics generic architecture for healthcare applications. Architecture of health care data analytics As health sector data is moving toward really big data, thus better tools and techniques are required as compared to traditional data analytics tools. Traditional analytics tools are user friendly and transparent as compared to big data analytics tools that are complex and programming intensive and required variety of skills. Some famous big data analytics tools are summarized in Table 1. What is disease prevention and its challenges Every year millions of people die of preventable death [1]. In 2012, about 56 million people died worldwide and two-thirds of these deaths were due to non-communicable disease including diabetes, cardiovascular and cancer. Moreover, 5.9 million children died in 2015 before reaching the fifth year of their life and most of these death were due to infection (i.e., diarrhea, malaria, birth asphyxia, pneumonia etc.); however, this number can be reduced to half at least by treating or preventing through the access to simple affordable interventions [2]. Core problem in healthcare sector is to overcome the huge number of causalities as well as reduce the cost. The goal is to reduce the prevalence of disease, help people to live longer and healthier life as well as reduce the cost. One of the main interests in disease prevention is driven by the need to reduce the cost. The lifetime medical expenditures are increased from $ 14k to $ 83k per person and this increase is up to 160K after the age of 65. Thus, the proportion of average world GDP devoted to healthcare sector is increased from 5.28% in 1995 to 5.99% in 2014 and is expected to increase in future (i.e., from 17.1% in 2014 to 19.9 of US GDP by 2022%) [3, 4]. This increase in medical expenditures is mainly due to the aging and growing populations, the rising prevalence of chronic diseases as well as for infrastructure improvement. Thus, the cost-saving and cost-effective preventive solutions are required to reduce the burden on economy. Traditional preventive measures mainly focus on promotion of healthcare benefits. The cost-effectiveness ratio is said to be unfavorable when intervention incremental cost are larges relative to the healthcare benefits. USA spent 90% of budget on disease treatment and their complication rather than prevention (only 2–3%) whereas many of these diseases can be prevented at first stage [5, 6]. Spending more on health does not guarantee of health system efficiency. The investment on prevention can help to reduce the cost as well as improve the health quality and efficiency. Health industry is facing considerable challenges in the promotion and protection of health at a time when there is huge pressure due to the considerable budgets constraints and resources in many countries. Early detection and prevention of disease plays a very important role in reducing deaths as well as healthcare cost. Thus, the core question is: How data can help to reduce the patients or disease effect in the population? Concept and traditional methodology Disease prevention focuses on prevention strategies to minimize the future hazards to health by early detection and prevention of disease. An effective disease management strategy reduces the risks from disease, slow down its progression and reduces symptoms. It is the most efficient and affordable way to reduce the risk of disease. Preventive measures strategies are divided into different stages, e.g., primary, secondary and tertiary. Disease prevention can be applied at any prevention level along with the disease history, with the goal of preventing its progression further. Primary It seeks to reduce the occurrence of new cases, e.g., stress management, exercises, smoking cessation to prevent lung cancer and immunization against communicable diseases. Thus, it is most applicable at the suspected stage of a patient. Strategies of primary prevention include risk factor reduction, general health promotion and other protective measure. This can be done by bringing up the healthier lifestyles and environmental health approaches through health education and promotion program. Secondary Purpose of secondary prevention is to either cure the disease, slow down its progression, or reduce its impact and is the most appropriate for those in the stage of early-stage or pre-symptomatic disease. It attempts to reduce the number of cases through early detection of the disease and reducing or halting its progression, e.g., detection of coronary heart patient after their first heart attack, blood tests for lead exposure, eye tests for glaucoma, lifestyle and dietary modification. Common approach to secondary prevention includes procedure to detect and treat preclinical pathological changes early through screening for disease, e.g., mammography for early-stage breast cancer detection. Tertiary The key aim of tertiary disease prevention is to enhance life quality of patient. Once the disease is firmly established and has been treated in its acute clinical phase, it seeks to soften the impact of disease on the patient through therapy and rehabilitation, e.g., tight control of type-1 diabetes, assisting a cardiac patient to lose weight and improving the functioning of stroke patient through rehabilitation program. Effective primary prevention to avert new cases, secondary prevention for early detection and treatment and tertiary prevention for better diseases management are not only to improve the quality of life but also helps to reduce unnecessary healthcare initialization. Extensive medicine knowledge and clinical expertise are required to predict the probability of patient that are contracting disease (Table ​(Table22). Challenges Un-automated analysis of huge and complex volumes of data is expensive as well as impractical. Data mining provides great benefits for the disease identification and treatment; however, there are several limitations and challenges involved in adapting DM analysis techniques. Successful prevention depends upon knowledge of disease causation, transmission dynamics, risk factor and group identification, early detection and treatment methods, implementation of these methods and continuous evaluation and development of prevention and treatment methods. Additionally, data accessibility (data integration) and constraints(missing, unstructured, corrupted, non-standardized data and noisy) add more challenges. Due to the huge number of patients, it is impossible to consider all those parameters to develop cost-effective and cost-efficient prevention system. The expansion of medical records databases and increased linkage between physician, patient and health record led the researcher to develop efficient prevention system. Healthcare applications generate mound of complex data. To transform this data into information for decision making, traditional approaches are lagging behind, and they barely adopt advanced information technologies, such as data mining, data analytics, big data etc. Tremendous advancement in hardware, software and communication technologies opens up opportunities for innovative prevention by provided cost-saving and cost-effective solution by improving the health outcomes, properly analyzing the risk and overcoming the duplicate efforts. Barriers to develop such system include non-standard (interoperability), heterogeneous, unstructured, missing or incomplete, noisy or incorrect data. Disease prevention mainly depends on the data interchange across different healthcare system thus interoperability plays major role in success of prevention system, whereas healthcare sector is still on the way. ISO/TC 215 includes standards for disease prevention and promotion. Standards are a critical component, whereas it is not yet mature in healthcare sector. Many stakeholders (HL7, ISO and IHTSDO (organization that maintain SNOMED CT) with aim to have common data representation are working to address semantic interoperability. Healthcare data is diverse and have different format. Moreover, with the rapid use of wearable sensors in healthcare results in tremendous increase in the size of heterogeneous data. For effective prevention methods, integration of data is required. For years, documentation of clinical data has trained clinician to record data in most convenient way irrespective, how this data could be aggregated and analyzed. Electronic health record systems attempt to standardize the data collection but clinician are reluctant to adopt for documentation. Accuracy of data analysis depends significantly on the correctness and completeness of database. It is a big challenge to find problems in data and even harder to correct the data, moreover data is missing. Using incorrect data will defiantly provide incorrect result. Whereas ignoring the incorrect data, or issue of missing data introduce bias into analysis that leads to inaccurate conclusion. For the extraction of useful knowledge from large volume of complex data that consist missing data and incorrect values, we need sophisticated methods for data analysis and association. Moreover, data privacy and liability, capital cost, technical issue are other factors. Data privacy is another major hurdle in development of prevention system. Most of the healthcare organizations have HIPAA certification; however, it does not guarantee the privacy and security of data as HIPAA is considering security and policy rather than implementation [7]. With the increase popularity of wearable devices, mobiles and online availability of healthcare data put it on emerging threat. In addition to that, it may increase racial and ethnic disparate because these may not be equally available due to economic barrier.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Impact XT – Precision Medicine - Biodiversity

Biodiversity loss causes extinction

Phil Torres, Scholar at the Institute for Ethics and Emerging Technologies, 5-20-2016, "Biodiversity Loss: An Existential Risk Comparable to Climate Change," Future of Life Institute, https://futureoflife.org/2016/05/20/biodiversity-loss/

Catastrophic consequences for civilization. The consequences of this rapid pruning of the evolutionary tree of life extend beyond the obvious. There could be surprising effects of biodiversity loss that scientists are unable to fully anticipate in advance. For example, prior research has shown that localized ecosystems can undergo abrupt and irreversible shifts when they reach a tipping point. According to a 2012 paper published in Nature, there are reasons for thinking that we may be approaching a tipping point of this sort in the global ecosystem, beyond which the consequences could be catastrophic for civilization. As the authors write, a planetary-scale transition could precipitate “substantial losses of ecosystem services required to sustain the human population.” An ecosystem service is any ecological process that benefits humanity, such as food production and crop pollination. If the global ecosystem were to cross a tipping point and substantial ecosystem services were lost, the results could be “widespread social unrest, economic instability, and loss of human life.” According to Missouri Botanical Garden ecologist Adam Smith, one of the paper’s co-authors, this could occur in a matter of decades—far more quickly than most of the expected consequences of climate change, yet equally destructive. Biodiversity loss is a “threat multiplier” that, by pushing societies to the brink of collapse, will exacerbate existing conflicts and introduce entirely new struggles between state and non-state actors. Indeed, it could even fuel the rise of terrorism. (After all, climate change has been linked to the emergence of ISIS in Syria, and multiple high-ranking US officials, such as former US Defense Secretary Chuck Hagel and CIA director John Brennan, have affirmed that climate change and terrorism are connected.) The reality is that we are entering the sixth mass extinction in the 3.8-billion-year history of life on Earth, and the impact of this event could be felt by civilization “in as little as three human lifetimes,” as the aforementioned 2012 Nature paper notes. Furthermore, the widespread decline of biological populations could plausibly initiate a dramatic transformation of the global ecosystem on an even faster timescale: perhaps a single human lifetime. The unavoidable conclusion is that biodiversity loss constitutes an existential threat in its own right. As such, it ought to be considered alongside climate change and nuclear weapons as one of the most significant contemporary risks to human prosperity and survival.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Impact XT – Precision Medicine - Biodiversity

Precision medicine lays the groundwork for advancements in ecotoxicology – that’s key to preserving biodiversity.

Bryan W. Brooks 4-12-2022. (Distinguished Professor, Environmental Science and Biomedical Studies Director, Environmental Health Science Program Editor-in-Chief, Environmental Science & Technology Letters Education Ph.D., Environmental Science, University of North Texas Bryan W. Brooks. "Precision Ecotoxicology and the Biodiversity Crisis." ACS Publications. Web. 4-12-2022. accessed 3-4-2023 < https://pubs.acs.org/doi/10.1021/acs.estlett.2c00133 >.) MSUCB

Basic and translational research progress in ecotoxicology remains critical to protect biodiversity and ecosystem services and to restore structural and functional damages when they occur in the environment. Perhaps you have heard a colleague say, “they won’t fund eco-”, or some similar construct when referring to chemicals and waste research ideas that may or may not fit within a specific funding body’s portfolio. Unlike many other developed countries, the sad reality is that competitive federal funding in the United States has not been consistently available for ecotoxicology research, and this has been the case for some time, despite pendulum swings in policy agendas. Perhaps this reality has resulted from historic perceptions of ecotoxicology as a descriptive science by some. Such perceptions, if they remain, are outdated and misinformed, because the discipline has matured to a mechanistic field of study. It is also important to appreciate that a lack of strategic support for ecotoxicology is foundationally detrimental to preparation of the environmental workforce, which includes academia, but routinely employs its basic and translational contributions much more broadly within diverse environmental management programs of businesses, government agencies, and nonprofits. Fortunately, a new age of ecotoxicology is beginning, and it promises reciprocal benefits for the environment and public health. The time has come to develop and advance a new subdiscipline, precision ecotoxicology, if we are to address the biodiversity crisis. Advancing precision ecotoxicology, which includes comparative ecotoxicokinetics and ecotoxicodynamics from the laboratory and the field, is necessary to engage biodiversity loss because species, and even down to individual organisms for threatened and endangered species, represent the key environmental management or protection goal. For other taxa, the population level of biological organization is commonly identified as the protection goal during prospective and retrospective chemical assessments. However, mechanistic understanding from molecular initiation events to adverse outcomes at the individual level is critical to fully understand chemical, physical, and biological threats and to protect biodiversity. For biodiversity hot spots experiencing significant environmental stress, protection goals associated with chemicals and waste management may need to be modified to also protect the individual, if we are to reduce the impacts of pollution on biodiversity. Precision ecotoxicology will inherently leverage advances in mechanistic, computational, and evolutionary ecotoxicology, molecular ecology and systematics, and precision medicine and environmental health science. Precision medicine, which is sometimes called personalized medicine, aims to define genetic differences within and among individuals, in combination with environmental and social factors, leading to diseases, in an effort to tailor interventions accordingly to specific people. In contrast to traditional approaches in medicine, it is advancing diagnosis, treatment, and prevention of diseases for the individual patient. Researchers are similarly advancing precision environmental health science, which similarly aims to understand underlying individual level susceptibilities to environmental exposures that elicit adverse human health outcomes. Precision medicine and environmental health science have leveraged completion of the human genome in 2003, and subsequent advances in pharmaco- and toxicogenomics. Such precision health efforts are important to environmental management of chemicals and waste because the individual level of biological organization represents the key protection goal during human health risk assessment, a practice that is thus analogous to protection goals for threatened and endangered species. Since completion of the human genome, genomes of thousands of other species have been assembled, and many more have been sequenced as costs of sequencing and annotation have precipitously decreased along with increased workforce capacity and throughput in bioinformatics. Such information is already supporting cross species extrapolation approaches (https://www.epa.gov/chemical-research/sequence-alignment-predict-across-species-susceptibility; http://ecodrug.org/), which are increasingly important for assessing and managing chemicals and waste. Precision ecotoxicology promises reciprocal benefits to human health as development of non-animal alternatives, alternative animal models (i.e., zebrafish), adverse outcome pathways, high-throughput chemical screening, and other new approach methodologies are progressing. This progress is necessary, in part, due to the U.S. Environmental Protection Agency’s recent decision to eliminate mammalian studies by 2035 (https://www.epa.gov/newsreleases/administrator-wheeler-signs-memo-reduce-animal-testing-awards-425-million-advance). In addition, when coupled with diverse green chemistry and engineering efforts, precision ecotoxicology will support innovation, including sustainable molecular design of less hazardous chemicals and technologies. But as precision ecotoxicology is developed to understand individual and subpopulation susceptibilities within a species, we need to continue to connect mechanistic pursuits to the population level of biological organization. In fact, precision ecotoxicology promises to advance an understanding of the often variable population level responses to chemical, physical, and biological stressors. Environmental Science & Technology Letters (ES&T Letters) aims to rapidly disseminate urgent and important contributions from the environmental science, engineering, and health communities. The journal specifically publishes papers that describe significant scientific advances or novel technologies within the broad field of environmental science and technology. Ecotoxicology and public health is a topical category within ES&T Letters. It will remain in focus for the journal, along with the other environmental science and engineering disciplines. Diverse connections among these critically important pursuits must be realized during basic and translational environmental studies, using mechanistically robust endeavors and systems-based approaches, because biodiversity matters to all of us.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Impacts – Syn Bio

That causes extinction

Thompson 18 Loren B Thompson, Ph.D. Loren B. Thompson is Chief Operating Officer of the non-profit Lexington Institute and Chief Executive Officer of Source Associates, a for-profit consultancy. Prior to holding his present positions, he was Deputy Director of the Security Studies Program at Georgetown University and taught graduate-level courses in strategy, technology and media affairs at Georgetown. He has also taught at Harvard University’s Kennedy School of Government. Mr. Thompson holds doctoral and masters degrees in government from Georgetown University and a bachelor of science degree in political science from Northeastern University. June 18th 2018 “Invisible Scourge The Danger of Chemical or Biological Attack on America is Growing Fast” https://www.lexingtoninstitute.org/wp-content/uploads/2018/06/6.18.18-LT-Invisible-Scourge-1.pdf

The Rise of Synthetic Biology The genetic information of almost all life forms is contained in a molecule of deoxyribonucleic acid (DNA) that is found in the nucleus of each cell in an organism's body. Without the information carried on this microscopic strand, the organism could not express its characteristic traits or reproduce. The role of DNA in transmitting inherited traits between generations of a species was first illuminated in 1953. During the 1970s, scientists began to discover methods of manipulating DNA so that traits could be added or removed from an organism's genetic makeup (or "genome"). The practice came to be called synthetic biology, because it involved fashioning features not known to exist in nature. One of the earliest applications of such gene editing was the modification of crops to make them less susceptible to drought or disease. At its inception, synthetic biology was difficult and expensive. That, plus safety and ethical concerns, limited the spread of knowledge concerning the emerging field. Over time, though, the tools for splicing and reassembling DNA became accessible to a broader array of users. Eventually, scientists learned how to create wholly new biological components and organisms. The most important breakthroughs came in 2009, in the form of a new gene editing tool known by the acronym CRISPR. To quote the National Human Genome Research Institute, "CRISPR is simpler, faster, cheaper, and more accurate than older genome editing methods." Unfortunately, the vast improvement in laboratory practices enabled by advances like CRISPR comes at a price. It has become much easier for users with destructive intent to apply synthetic biology to their work. For instance, a scientist sympathetic to extremist causes might create an organism combining the lethality and transmissibility of multiple pathogens to generate horrific effects. The result would be a super pathogen threatening the survivability of large populations, and even civilizations if no prompt countermeasures were available. This is no fanciful speculation: some scientists believe that humanity is only two mutations of the influenza virus away from species extinction. Unlike any other time in human history, it is now feasible to artificially spawn such mutations, and then loose them on unsuspecting targets. That is the danger of widely deploying dual-use technologies in synthetic biology. The same methods that might be used to defeat cancers could be used to destroy adversaries through virulent pandemics. That outcome might not even be deliberate: if super pathogens escape laboratories to reach the outside world, they might cause just as much damage even though their release was accidental. The federal government and scientific community have sought to fashion standards to minimize the likelihood of such catastrophes, but as knowledge spreads so does the danger. This would not be the first time emerging technology had unforeseen consequences, but it might be the last. Nicholas G. Evans of the University of Pennsylvania department of medical ethics and health policy observed in 2015 that "certain broad elements of synthetic biology, driven by the aim to create a predictable engineering discipline out of the life sciences, have the capacity to deskill the life sciences in a way that enables malevolent actors." Breakthroughs in microbiology might thus become major threats to national security.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Impacts – Syn Bio

Syn-Bio leadership is key to U.S. norms on biotech writ large – that allows the US to become more competitive with other countries

Gronvall, 15 – PhD, Johns Hopkins University Center for Health Security senior associate Gronvall GK. US Competitiveness in Synthetic Biology. Health Secur. 2015 Nov-Dec;13(6):378-89. doi: 10.1089/hs.2015.0046. PMID: 26690379; PMCID: PMC4685481.

Synthetic biology is an emerging technical field that aims to make biology easier to engineer; the field has applications in strategically important sectors for the US economy. While the United States currently leads in synthetic biology R&D, other nations are heavily investing in order to boost their economies, which will inevitably diminish the US leadership position. This outcome is not entirely negative—additional investments will expand markets—but it is critical that the US government take steps to remain competitive: There are applications from which the US population and economy may benefit; there are specific applications with importance for national defense; and US technical leadership will ensure that US experts have a leading role in synthetic biology governance, regulation, and oversight. Measures to increase competitiveness in S&T generally are broadly applicable for synthetic biology and should be pursued. However, the US government will also need to take action on fundamental issues that will affect the field's development, such as countering anti-GMO (genetically modified organism) sentiments and anti-GMO legislation. The United States should maintain its regulatory approach so that it is the product that is regulated, not the method used to create a product. At the same time, the United States needs to ensure that the regulatory framework is updated so that synthetic biology products do not fall into regulatory gaps. Finally, the United States needs to pay close attention to how synthetic biology applications may be governed internationally, such as through the Nagoya Protocol of the Convention on Biological Diversity, so that beneficial applications may be realized.

Synthetic biology is an emerging new technical field that aims to make biology easier to engineer and more amenable to rational design, so that biological traits, functions, and products can be programmed like a computer. The concept of engineering biology is not a new one, nor is synthetic biology the first instance in which biology has been declared engineerable.1 Stephane Leduc wrote about the concept in the early 1900s.2 In 1974, the renowned cancer biologist Waclaw Szybalski described then-current work on molecular biology as the “descriptive phase,” adding that the real challenge will begin “when we enter the synthetic biology phase of research in our field. We will then devise new control elements and add these new modules to the existing genomes or build up wholly new genomes.”3(p23) Though what is now termed synthetic biology is not wholly distinct from previous studies of genetic engineering, the ability to fruitfully accomplish bioengineering is much greater now than it has been at any other point in history. Thanks to advances in computing power; the ability to rapidly, reliably, and inexpensively synthesize long tracts of DNA; new tools to reliably edit genomes; an increased understanding of biological systems; and the enthusiasm of young scientists who want to enter the field, synthetic biology is a new field and a new phenomenon, which proponents believe could revolutionize medicine and manufacturing.4-7

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Internal link XT– Precision Medicine

BioPharma research is appreciating the trend to cell, gene, and AI therapies – directed toward precision medicine

Contralant, March 20, 2023 The new frontiers of pharmaceutical innovation – according to investors ​ https://www.pharmaceutical-technology.com/sponsored/the-new-frontiers-of-pharmaceutical-innovation-according-to-investors/

Although appreciating the momentum behind pharmaceutical innovation can help entrepreneurs plan for the future, many are still grappling with supply chain and cost pressures in the present. High interest rates mean investors are wary and loans are harder to come by. Firms seeking to raise capital, expand their scope and maintain profitability need to scrutinise their operational efficiency. A renewed focus on supply chain durability can help pharma firms weather present storms and prepare them for changes coming down the line. In addition to providing an end-to-end view of supplier resilience and performance – allowing costs and inefficiencies to be identified and ironed out – modern supply chain monitoring platforms incorporate AI technology, enabling development of increasingly personalised customer engagement strategies. In a world where fine margins are dictating where investors will or will not invest, creating a supply chain that is both efficient and tech-forward today will help rake in funding tomorrow. “Trends such as the focus on cell and gene therapies and the use of AI technology have a knock-on effect for the future of the pharma supply chain, which will need to cater to more individualized therapies,” says Adalheidur Pálmadóttir, VP business development at Controlant. “Changes on the horizon include real-time unit-level tracking, the ability to ramp up and down manufacturing on a massive scale, and the ability to use just-in-time delivery systems across production lines.” Irrespective of size, region or research area, any pharma firm aiming to attract investment must contend with these key trends. “Placing resilient, efficient supply chains at the heart of their operations is imperative,” says Pálmadóttir. “A real-time visibility platform, command centre, and IoT devices are the foundation of digitalised, automated, sustainable supply chains, which is why some of the world’s biggest pharma companies are already working with Controlant.”

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

Single payer is expensive and hampers medical innovation

Ted Gaines June 21, 2017, “My Turn: Single-payer healthcare”, Village Life, https://www.villagelife.com/commentary/my-turn-single-payer-healthcare/

Are you ready for California to double your taxes? What about triple or quadruple them? A bill currently making its way through the state Legislature could push tax rates up beyond imagination, making us tax serfs to the state and driving hundreds of thousands of jobs out of California. Senate Bill 562, the “California Healthcare for All Act,” proposes to ban private insurance coverage and force every resident in the state into the equivalent of the Medi-Cal system we provide for the poor and disabled, where state-provided healthcare would be the only option. The costs would be staggering. A recent analysis by the California Senate Appropriations Committee estimated that implementing SB 562 would set back California taxpayers $400 Billion. This year’s general fund spending — including roads, schools, universities, prisons and more — is estimated around $124 billion. In a highly taxed state that just recovered from years of massive deficits and still teeters on the edge of fiscal ruin, where is this additional taxpayer money supposed to come from? Four hundred billion is more than $10,000 a year from every man, woman and child in the state. Do most California families have that kind of money lying around? That extraordinary cost is consistent with estimates from other states and is the major reason that single-payer schemes have been voted down or abandoned before implementation. New York state is currently proposing its own SB 562. In 2019, when New York’s plan would be active, the state expects to collect $82 billion in taxes, but would need another $91 billion to pay for its single-payer scheme. New York, as is the case with California, will more than double its overall revenue. See a trend? And that $91 billion number might be charitable. An analysis by healthcare expert Avik Roy concluded that New York’s plan could cost $226 billion a year, nearly quadrupling the state’s current tax collections just to pay for healthcare, not government’s other responsibilities. Roy estimates that the plan would jettison 175,000 jobs from the state, as “high-wage, high-value industries move to neighboring states” as a result. California, a much larger state, could shed hundreds of thousands of jobs under SB 562’s crushing fiscal mandate. California’s plan also proposes to pay for all care for all residents, regardless of whether they are in the state illegally or whether they are here legally but just moved here to take advantage of the state’s “free” medical care. California, already the king of the tax dollar giveaway, would become the hot new destination for immigrants and indigents seeking care, driving the costs even higher. And, even if the costs were not fantastically, impossibly high, SB 562 presents other problems for California healthcare. Our state suffers from a shortage of healthcare providers, particularly in rural and inner-city areas, a condition that would only be intensified by the provider rate caps in the bill. Single-payer systems are also prone to deadly wait times since they ration care to reduce costs. The United States is a medical innovator and California is the nation’s bioscience hub. That will disappear in the price-controlled, socialized system California legislators are trying to dump on the people. Price caps, a key component of single payer plans, spell doom to medical innovation. Remaking the entire healthcare system is a terrible idea if the reform is going to make healthcare slower, less innovative and wildly more expensive. SB 562 is an ill-advised plan with unpayable costs that would make California taxpayers sick.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

Empirically, countries with universal health care have lower rates of innovation. Public intervention means little incentive to introduce tech or prolong life.

Jacob James Rich Policy Analyst April 16, 2019 Medicare for All Means Innovation for None https://reason.org/commentary/medicare-for-all-means-innovation-for-none/

Public health care has little incentive to introduce new technologies and prolong life. Rich countries like the  and  provide universal health care but have lower cancer survival rates than America. That’s why many more American seniors today have health insurance than in 1965, yet their health outcomes are still often terrible. And more funding isn’t enough — Medicare already  treatments, but lacks the mechanisms and competition to decide which are effective. This might be why up to  of Medicare claims are fraud and waste.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

Single payer discourages innovation and has an extremely high economic cost

June 2, 2017, “The California Senate Passes a Single-payer Health Care Bill Without a Funding Mechanism”, Washington Policy, Stark is the health care policy analyst at Washington Policy Center and a retired physician,

Yesterday, the California Senate passed a bill to create a state-wide, single-payer health care system. () The bill now moves on to the state Assembly for consideration. The cost estimate for a single-payer system in California is at least $400 billion per year. No funding mechanism is included in the Senate bill. Vermont and Colorado considered a state single-payer system. After much enthusiasm, Vermont officials pulled the plug on the legislation when it became clear that the cost would be prohibitive. () The state budget is in the $5.7 billion range per year. A single-payer system would have required an additional $2 billion (a 35 percent increase) in addition to multiple federal waivers. Even hard-core supporters such as the governor realized Vermont couldn’t afford the plan. Colorado voters recently rejected a single-payer system, again because of the extremely high cost and the impact on the vast majority of people in the state who already had health insurance. Support continues for a single-payer system both nationally and in Washington state. Bills have been dropped in the last few legislative sessions in Olympia. The most recent bill did not make it out of committee. () Nationally, former presidential candidate Senator Bernie Sanders and many on the left continue to push for a single-payer health care system in spite of the devastating drag it would have on the U.S. economy. () As the debate over health care reform rages on, more Americans are considering adoption of a single-payer health care system. The Affordable Care Act (ACA), also known as Obamacare, is a highly complex law and has made our current health care delivery system more confusing. A single-payer system is attractive to many people because of its perceived simplicity – the U.S. government would provide direct health services to all Americans. Canada has had a single-payer system for over 30 years and its experience is revealing. Canadians are proud of the fact that every citizen has health insurance. From a cultural standpoint, the principle of universal coverage is a priority for the country. It also makes it easier for the citizens to overlook the problems within the system. The demand for health care far outweighs the supply of care. Long wait times in Canada are not in the patient’s best interest and would not be acceptable for the vast majority of Americans. Health care rationing through waiting-lists is effective when supply is overwhelmed by demand. The question is whether government bureaucrats should have the authority to pick and chose what procedures patients receive and who should actually receive those treatments, while others are forced to wait for care. A single-payer system discourages innovation. There is virtually no money in the system to encourage investment in new life-saving medicines and medical devices. Lack of innovation guarantees that no new treatments will be discovered, with no improvement in quality of life or life expectancy. Under a single-payer system, health care spending must compete with all other government activity for funding. This makes health care very political and subject to change with every new budget. It also forces each health care sector, for example hospitals and doctors, to compete with each other for limited money. Fundamentally, a single-payer system centralizes all health care with the government. Bureaucrats, not patients and their providers, get to make life and death decisions about the kind and amount of health care people receive. A single-payer system sounds simple and egalitarian, but the reality is very different.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

Single payer stifles innovation and harms the economy

JESSE PINES JUNE 3, 2016, “Single Payer Healthcare: Beyond the Rhetoric”, Emergency Physicians Monthly, http://epmonthly.com/article/single-payer-healthcare-beyond-rhetoric/

Yet there are many potential downsides to single payer systems. Importantly, single payer would dramatically increase government controls and increase the size of the government. While government is clearly necessary to administer many public goods such as defense and infrastructure, there is concern that government control might lead to mismanagement and misallocation of resources in healthcare, reducing the quality of care over time. With less incentive for private industry to fill market needs because of lower profits and increased regulation, this could result in major slowdowns in innovation, fewer new technologies to treat patients and improvements in healthcare delivery. For example, a recent report found that Canada ranked last in 11 OECD countries when it came to the time required to wait for an appointment with a family physician [3]. Waiting times for specialists in Canada average more than 18 weeks. These waiting times have been associated with higher mortality rates, with females being most affected with an increase in 3 deaths per 100,000 population due to waiting times alone in a recent report from the Frasier Institute [4]. There is also concern about the disruption to the economy that single payer would bring. Lower administrative costs would result in a major shrinkage of the insurance industry and other parts of the healthcare industry, which currently makes up more than 17% of the U.S. economy. This would result in the loss of jobs for many Americans. With less money in healthcare, this could also reduce the quality of workers who choose to pursue healthcare careers, particularly given sky-high costs of medical education in the United States compared to other countries. Finally, there are concerns that single payer would further support the concept of the welfare state, where people would have less incentive to work with greater support from the government for their basic needs. The more important question is whether single-payer is even possible given the way the political system is set up in the United States. In the U.S., politicians must continuously raise money from campaign donors in order to stay in office and, in turn, become beholden to those donors. Donors who have a lot to lose with a move to single-payer have and would lobby vigorously to avoid disrupting the status quo and their business models. Ever year since 2002, the United States National Health Care Act, which would establish a single payer system in the United States has been introduced by John Conyers (D-MI). However, the bill has never been advanced. In addition, several state proposals have been put forward, but all have ultimately failed. The closest state to advance the idea was Vermont’s Green Mountain Health Care (GMC), which was passed in 2011. GMC was not a strict single-payer system because it still allowed private insurers to operate in the states. However, ultimately Vermont’s plans were abandoned in December 2014, with concerns over costs being too high and tax increases. Ultimately, don’t hold your breath waiting for the United States to implement single payer healthcare. While there are clearly potential benefits, the United States will not adopt single payer without a dramatic change in the way that political campaigns are funded. Despite this, there are reasons to be hopeful that U.S. healthcare policy will work to achieve some of the same goals – specifically lower healthcare costs and higher rates of insurance – in other ways. The Affordable Care Act (ACA) of 2010, for example, has many provisions that have reduced the numbers of uninsured in other ways, such as through Medicaid expansion and insurance exchanges. Provisions in both the ACA and the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 will also test and implement new ways to pay and measure quality of care for providers that may also place similar downward pressure on costs, while leaving intact the capitalism in American healthcare. However, the long-term ability of these laws to impact care quality and outcomes, and overall costs still remains an open question.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

US subsidizes a majority of global medical R&D- single payer decks this

Reconsider Media January 19, 2017, “”, Reconsider Media, http://www.reconsidermedia.com/lastestarticles/the-surprising-argument-against-single-payer-healthcare-in-the-united-states

Whether you're for in the United States or against it, you're probably familiar with a whole bunch of arguments that fly around in favor of it, or against it (ideally, you hear them in favor of some other system, rather than a flat-out refusal, but take what you can get). While I shall neither advocate for nor against single payer here, I wanted to point out a potential consequence of the United States adopting single payer insurance that I have not yet seen spoken elsewhere. Drug and medical device companies in the United States have massive profits, especially compared to other countries--this is due for many reasons. People have argued--likely correctly--that a single payer system would create a powerful government (like a monopoly, but it's the buyer rather than the seller), that would be able to negotiate very low prices and thus slash drug and medical device company profits. Sounds great so far. Here's where things get interesting. Because the United States is both a very large and wealthy country, and also is a country in which drug and device companies can make very large profits, it actually accounts for the majority of these companies' profits--. In other countries, drug and device companies make razor-thin margins on their products. This means that when drug and device companies are calculating the potential Return on Investment (ROI) for bringing a new device or drug to market, the majority of the Return is bucketed within the United States. Were the United States to create a structure that slashed drug and device company profits to the levels of rich single payer nations (which would be something like an 80%+ reduction in profits), then the total profit for the company would drop dramatically--about 50% total. Why would this be a bad thing? Let's look at the cost to bring a new drug to market. The FDA and other agencies have very stringent tests required to bring a drug to market. In addition to the research and development required, the regulatory and testing costs bring the total average cost to well over $2.5 billion dollars. This number has actually , as these regulations grow tighter. To overcome this cost and create a profitable product, drug companies need to take a bet that the drug is going to make that money back, and then some, in a reasonably short period of time. Bringing a drug to market is already dicey--most by far don't make it through R&D, and still more don't make it past the FDA and other regulatory bodies. Many lose money, others make very little, and some are cash cows that rake in a lot of money--at least while the drug company has a patent (the abuse of which is another story altogether). After the patent expires, generics show up and all but eliminate margins per drug. Medical devices face much lower costs, , though that's only for their regulatory costs. But their margins tend to be lower, as their patents are harder to enforce, and others can move in easily. The upshot of this is that if drugs and devices become far less profitable, then far fewer are going to pass the ROI calculation hurdle. In a regime of global low margins, most drugs and devices cannot be depended upon to make back the $2.5B or tens/hundreds of millions, and therefore will never be developed in the first place. A friend of mine that is the CEO of a medical device startup is currently bottlenecked by fundraising for regulatory approval; luckily for him, the potential for profit is fairly high. But already, it's a dicey proposition to inv: if the US adopts a low-margin single payer system, the rate of innovation and product development in the drug and medical device market would slow down dramatically. In short, high American costs are subsidizing the innovation of new medical drugs and technology for the entire world. If the US stops subsidizing these costs, innovation will slow, and new, potentially live-saving drugs will either never make it to market or make it much further down the line estors. What will happen is this. I don't make the case that the US should strictly speaking not adopt single payer healthcare for that reason, but it's a consequence that will occur if the US does, and should be part of the equation. It's important that this be part of the bigger discussion on single payer healthcare in the United States, and it's hopefully a good lesson in thinking through all of the potential unintended consequences of sweeping economic reforms.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

Single payer cuts innovation in half by price negotiation – global examples prove

Leonard Pitts Jr., 3-8-2016, http://www.philly.com/philly/opinion/20160308_Op-ed__Single-payer_health_care_unworkable__too_costly.html, "Op-ed: Single-payer health care unworkable, too costly," Philly, Acc:9-16-2017 (ermo/sms) [abbraviations added]

The real problem with a single-payer system, however, is much simpler: The approach has failed everywhere it has been tried - from Europe to Canada to Sanders' own state of Vermont. In almost every instance, government-run health care has suppressed medical innovation and made it harder for patients to get the treatment they need at a price they can afford. Both candidates ought to be discussing practical ways to fix our health system's most serious flaw - too much government intervention. Instead, they're quibbling over the many faults of a single-payer program that would dramatically lower the quality of care for all Americans. While he has yet to provide many serious details, Sanders' proposal creates a single-payer health program that would "cover the entire continuum of health care," from inpatient care to hearing, vision, and oral health. Sanders tends to frame his plan as a way to "join every other major industrialized nation on Earth and guarantee health care to all citizens." But one need only look at these other nations to understand why Sanders' vision is a step in the wrong direction. As anyone who has ever stood in line at the Department of Motor Vehicles can understand, government-run systems are invariably wracked by inefficiencies. When it comes to health care, one size doesn't fit all. For instance, Canadian patients hoping to see a specialist physician can expect to wait more than 18 weeks. An MRI scan in that country takes more than 10 weeks. Waiting times have grown so long in Sweden's single-payer system that one in 10 citizens has opted for private coverage. In order to contain health costs, Sanders promises to "stand up to drug companies and negotiate fair prices for the American people." But again, the disastrous effects of drug price controls have been clearly demonstrated throughout Europe. To take one example, the United Kingdom's National Health Service (NHS) consistently denies patients access to the most up-to-date treatments if they are deemed too expensive by regulators. These decisions often lead to avoidable suffering for those in need of care. Last summer, in fact, British health administrators refused to pay for a breakthrough ovarian cancer drug until patients had undergone three rounds of chemotherapy. Drug price controls also come at the expense of medical innovation, as they weaken the incentive for pharmaceutical firms to invest in [R&D] research and development. In the 1970s, four European countries invented 55 percent of the world's new drugs. Decades of increasing price controls in Europe pushed drug development efforts - representing hundreds of billions of dollars of investment and economic activity - to the United States. Between 2000 and 2010, those four countries accounted for a third of pharmaceutical innovation, while the U.S. share rose to 57 percent. The nonpartisan National Bureau of Economic Research cautions that "cutting [drug] prices by 40 to 50 percent in the U.S. will lead to between 30 to 60 percent fewer R&D projects being undertaken." Less research means fewer new medicines and fewer lives saved.

Medicare for All collapses entrepreneurship and innovation

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

Medicare for all decks econ and stifles innovation while restricting access to care

Richardson 20 [Valarie Richardson, Valerie Richardson covers politics and the West from Denver. “The Washington Times”, published March 23, 2020, , accessed 6/29/23]/hacchs

Leading economists warn ‘Medicare for All’ would trigger shortages, stifle innovation Universal health-care proposals gain steam with Democrats More than 50 leading U.S. economists and professors have signed an open letter warning that the proposed “Medicare for All” plans to place Americans on a government-run system would trigger shortages, degrade quality and discourage medical innovation. “Americans should have access to the health care they need and have insurance protection for medical expenses they cannot afford,” said the letter released last week. “We, the undersigned economists, believe the proposed Medicare for All plans would lead to shortages throughout the health sector that would restrict access to care, undermine quality, lead to innovation-stifling price controls, and adversely impact the economy.” The 55 signers include Michael Boskin, who chaired the White House Council of Economic Advisers under President George H.W. Bush; former Office of Management and Budget director James Miller III, and Chapman University professor Vernon L. Smith, a 2002 Nobel Laureate in economic sciences. Medicare for All, a form of universal health care, has gained popularity with Democratic voters and candidates, although the front-runner for the 2020 Democratic presidential nomination, former Vice President Joseph R. Biden, suggested earlier this month that he would veto any such legislation. In their letter, the economists said that the nation “does not have a properly functioning market in the health sector due in part to the reimburse-the-supplier insurance model, but the solution is not more and bigger government.”

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

Medicare for All will collapse innovation – cost controls will cut biopharma profit and incentive for development

Henry Grabowski and Richard Manning JUNE 2, 2017 Drug Prices And Medical Innovation: A Response To Yu, Helms, and Bach https://www.healthaffairs.org/content/forefront/drug-prices-and-medical-innovation-response-yu-helms-and-bach

Essentially, the authors imply that the US price premium could be significantly reduced without affecting research and development investments or having other adverse effects. This is a strikingly bold and unfounded conclusion. There is no sound economic rationale to suggest that price ratios across countries or revenue premiums in the United States should match current research and development spending. Hence, the fact that price differences and research and development spending levels fail this arbitrary test does not offer a basis for sound policy making.

The issue of drug prices is always controversial, but in today’s politically charged environment, it seems particularly important to carefully evaluate this post’s methods and conclusions—and to do so through the lens of the economic principles that drive companies to search for new medicines and set prices for them. Thought leaders and policy makers would be well advised to approach this issue with a clear-eyed view of facts and underlying principles that govern economic behavior.

2023 SDI Negative
MSDI Case Neg vs Medicare for All › Innovation DA › Link Extension

Current US healthcare policy ensures global pharmaceutical innovation – the aff’s expansion of coverage sacrifices it

Huber, 2017 (Ryan, Executive editor of Arc, Ph.D. in Ethics, Assistant Professor of Christian Ethics at Fuller Theological Seminary, “U.S. Health Care Reality Check #1: Pharmaceutical Innovation”, Arc, 3/29/2017, https://arcdigital.media/u-s-health-care-reality-check-1-pharmaceutical-innovation-574241fb80ba)

There are several important reasons why health care is so expensive in the United States, and Grossman points out perhaps the most important: the United States effectively subsidizes research and development of drugs and medical devices for the rest of the world. As Grossman notes, other advanced nations “clamp down” on the profit motive in various ways, meaning that people who would normally make more money in a free market through developing new medical devices, medications, or procedures to produce better health care outcomes and perhaps drive down prices through competition have less incentive to do so in these more government-controlled health care systems. [Figure Omitted] That is, despite the many regulations and laws aimed at consumer protection and safety that do exist in the United States, our health care market is relatively freer and more dynamic than those of other developed countries. This leads to a high rate of medical and pharmaceutical innovation that ends up benefiting the rest of the world, particularly other rich countries, in a similar way that NATO nations, for example, benefit from close military alliance with the United States. In short and somewhat reductive terms: we spend more money so everyone else can be healthier. [Figure Omitted] But this doesn’t make total sense at first. If the United States is developing more innovative medicines, devices, and procedures than every other advanced economy, why aren’t we making money by selling these medical innovations to others for a hefty profit? Why aren’t there many more billions of dollars of revenue coming into the United States Treasury because of our status as a medical innovator? The answer is complicated, but here are some facts you need to know: First, pharmaceutical companies which innovate in the United States charge their domestic customers much more than they do their customers abroad. This is because, if countries don’t like the prices charged by a given pharmaceutical company for a certain drug, they will simply ignore the patent that company holds for their drug in the United States or elsewhere. Novartis spent nearly 15 years seeking a patent in India for Glivec, a medicine for chronic myeloid leukemia. That quest reached its dead end, at last. India’s Supreme Court rejected the Swiss drugmaker’s patent application. Glivec (marketed in America as “Gleevec”) is a blockbuster, earning the Swiss drugmaker $4.7 billion last year. Its prospects in India are now zilch. Although in this example Novartis happens to be a Swiss drug company, the ruling sends the same clear message to drug makers in the United States: Give us your drugs for next to nothing or you’ll get exactly nothing. [Figure Omitted] Second, and relatedly, notice that there seems to be a correlation between how much a country spends on prescription drugs and the percentage of NMEs (New Molecular Entities) produced by that country. If you combine points 1 and 2, you start to understand that the high spending of health care consumers in the United States is arguably funding not only global pharmaceutical innovation but is also facilitating the availability of new medicines to other countries at much lower prices than domestic consumers pay. There is a third factor that might help explain why health care, especially with regard to pharmaceutical innovation, is so much more expensive in the United States: our massive regulatory agency of all things drugs and food, also known as the FDA, is significantly more burdensome for medical innovation than the analogous agency for all of Europe, the EMA (European Medicines Agency). [Figure Omitted] The EMA doesn’t get the final say on whether a drug gets approved for sale in the EU, and perhaps even more significantly, they don’t breathe down their drug companies’ necks during clinical trials. [Figure Omitted] In the U.S., because of the cumbersome bureaucracy of the FDA and its processes, we decide to tackle more targets in the drug development scene through “Fast Track” and “Breakthrough Therapy” route than through the more traditional and more costly standard drug approval processes. Does this represent an implicit admission that government is inefficient? The breakthrough therapy designation was created by the FDA Safety and Innovation Act, a law that requires the agency to fast-track promising drugs for serious or life-threatening conditions. The FDA aims to do this by meeting early and often with developers, as well as working with them to design clinical trials that deliver the needed data quickly and efficiently. It’s understandable that, given limited resources, the regulatory process can’t be automatic, or even fast-tracked, for all applicants. But if the FDA can put a medication on a path where an evaluation can be made “quickly and efficiently,” does that mean the normal course of action is to proceed slowly and inefficiently? If so, this could represent a needless driver of health care costs. We need to be able to ask this question: Is there something going wrong with the drug development process to have the costs so high and climbing higher every year? [Figure Omitted] Looking at a cost breakdown of Big Pharma companies from 2014, a big chunk of their costs, almost equal to the sum of the entire first and second phase of their clinical trials, come from the 4th phase of clinical trials, which is often referred to as “post-marketing surveillance.” This is the phase of a drug’s life that takes place after its approval for sale on the U.S. market, in which the FDA requires continued and ongoing studies to validate the drug’s safety and efficacy using data generated from every phase of clinical trials leading up to its approval in the first place. It’s in this phase of a drug’s life where, after spending large amounts of money to get the drug approved, companies can still watch as the FDA rescinds a drug’s approval status, which leads to the drug getting withdrawn from the market, in many cases never to be seen again. In fact, as of 2015, 462 medicinal products were withdrawn from the market between 1953 and 2013, and the supporting evidence in 72 % of cases consisted of anecdotal reports. Only 43 (9.34 %) drugs were withdrawn worldwide and 179 (39 %) were withdrawn in one country only. Withdrawal was significantly less likely in Africa than in other continents (Europe, the Americas, Asia, and Australasia and Oceania). So, not only is almost a fourth of a drug’s average R & D cost attributable to legislative constraints the government imposes on pharmaceutical companies to police their own products even after they’ve been approved based on incredibly high standards of safety and testing, but also, compared to less developed countries, we’re more likely to pull drugs off the market and revoke their status as a result of anecdotal case reports of adverse effects that generally go unverified. We consistently decide to err on the side of safety, even if it means pulling the plug on a 10–15-year-long investment (the average length of development for a drug), which helps clarify how aspiring for safer and more effective drugs begins to preclude cheaper drugs. So the United States produces the most novel and cutting edge therapeutic compounds despite the most expensive and stringent approval process and sells them to other countries at much lower prices than we do at home. In doing this, we are indeed subsidizing research and development of drugs and medical devices for the rest of the world. This subsidized medical innovation is a major contributing factor to the out-of-control health care costs in the United States, and losing this innovation will be one of the sacrifices we make if we move toward a more cost-controlled or government-run health care system over the next several years.